drugset / Trial / NCT01374568

Changes in Bone Turnover With Increased Incretin Hormone Exposure

NCT01374568

Phase 4 Terminated 6 enrolled University of Alabama at Birmingham
RandomizedParallel-groupDouble-blindHealth-services research

Summary

The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.

Timeline

Start
2010-07
Primary completion
2012-07-06
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sitagliptin Small molecule 100 mg